multiple myeloma


Also found in: Thesaurus, Medical, Financial, Acronyms, Encyclopedia, Wikipedia.

multiple myeloma

n.
A malignant proliferation of plasma cells in bone marrow causing numerous tumors and characterized by the presence of abnormal proteins in the blood.

mul′tiple myelo′ma


n.
a malignant plasma cell tumor of the bone marrow that destroys bone tissue.
[1895–1900]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.multiple myeloma - myeloma that develops in several places at the same time
myeloma - a tumor of the bone marrow (usually malignant) composed of cells normally found in bone marrow
References in periodicals archive ?
M2 PHARMA-August 30, 2019-European Commission Approves Empliciti Plus Pomalidomide and Low-Dose Dexamethasone for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
ENPNewswire-August 23, 2019--Genmab Announces Approval of DARZALEX in Frontline Multiple Myeloma in Japan
21, 2019 (HealthDay News) -- Patients with a form of blood cancer known as multiple myeloma who haven't responded to other therapies might have a new weapon against the disease, researchers say.
Bristol-Myers Squibb Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion on a Type-II variation application for Empliciti (elotuzumab) plus pomalidomide and low-dose dexamethasone (EPd) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI), and have demonstrated disease progression on the last therapy.
-- (BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion on a Type-II variation application for Empliciti (elotuzumab) plus pomalidomide and low-dose dexamethasone (EPd) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI), and have demonstrated disease progression on the last therapy.
M2 EQUITYBITES-July 15, 2019-Janssen submits BLA to US FDA seeking approval of new DARZALEX (daratumumab) subcutaneous formulation for multiple myeloma
Global Banking News-July 15, 2019-Janssen submits BLA to US FDA seeking approval of new DARZALEX (daratumumab) subcutaneous formulation for multiple myeloma
FDA has lifted the partial clinical hold placed on CANOVA (M13-494), a Phase 3 trial evaluating venetoclax for the investigational treatment of relapsed/refractory multiple myeloma. The CANOVA trial evaluates venetoclax in combination with dexamethasone versus pomalidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma positive for the translocation (11;14) abnormality.
* REVLIMID in combination with bortezomib and dexamethasone (RVd) in adult patients with previously untreated multiple myeloma who are not eligible for transplant
OncoTracker said the acquisition of two patents offer clinical utility for multiple myeloma patients.
KEYWORDS: Newly diagnosed multiple myeloma, international scoring system, disease staging.
Evolmela is used as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma and the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.

Full browser ?